Value of Serum 3-Nitrotyrosine, Serpin Protease Inhibitors B1 Levels in Predicting Prognosis of Elderly Patients with Acute Ischemic Stroke after Intravenous Thrombolysis

doi:10.3969/j.issn.1673-5765.2023.12.011

Abstract

Abstract: Objective To explore the value of serum 3-nitrotyrosine (3-NT) and serpin protease inhibitors B1 (SerpinB1) levels in predicting prognosis of elderly patients with acute ischemic stroke after intravenous thrombolysis.
Methods Elderly (≥65 years old) patients with acute ischemic stroke treated in the Department of Neurology, Yan'an University Affiliated Hospital from January 2019 to January 2021 were prospectively and continuously included. According to 90-day mRS score, patients were divided into good prognosis group (0-2 points) and poor prognosis group (>2 points). Serum 3-NT and SerpinB1 levels were collected at baseline and before thrombolysis. Multivariate logistic regression was used to analyze the risk factors of poor prognosis.
Results A total of 80 elderly patients with acute ischemic stroke who received intravenous thrombolytic therapy were included, including 45 patients in the good prognosis group and 35 patients in the poor prognosis group. The SerpinB1 level in the poor prognosis group was higher than that in the good prognosis group [(75.24±8.54) ng/mL vs. (57.32±5.68) ng/mL, P<0.001], and the 3-NT expression the in poor prognosis group was also higher than good prognosis group [(75.67±11.22) ng/mL vs. (61.68±11.54) ng/mL, P<0.001]. ROC curve showed that when the 3-NT cutoff value at 70.23 ng/mL, the sensitivity and specificity of predict value of prognosis for acute ischemic stroke in the elderly were 72.54% and 73.28%. When the cut-off value of SerpinB1 was 68.17 ng/mL, the sensitivity of predict value of prognosis for acute ischemic stroke in the elderly was 66.55% and the specificity was 78.64%. Multivariate regression analysis showed that the high NIHSS score (OR 6.404, 95%CI 3.993-10.271, P<0.001), high SerpinB1 expression (OR 26.154, 95%CI 11.460-59.690, P<0.001) and high 3-NT expression (OR 12.769, 95%CI 4.635-35.174, P<0.001) were the risk factors for poor prognosis of intravenous thrombolysis in elderly patients with acute ischemic stroke.
Conclusions Baseline serum 3-NT and SerpinB1 have certain value in the prognosis assessment of elderly patients with acute ischemic stroke after intravenous thrombolysis.

Key words: 3-nitrotyrosine; Serine protease inhibitors B1; Acute ischemic stroke; Prognosis

摘要： 目的探讨及研究血清3-硝基酪氨酸（3-nitrotyrosine，3-NT）、丝氨酸蛋白酶抑制剂B1（serine protease inhibitors B1，SerpinB1）水平对老年急性缺血性卒中患者静脉溶栓预后的预测价值。
方法前瞻性连续纳入2019年1月—2021年1月延安大学附属医院神经内科收治的老年（≥65岁）急性缺血性卒中静脉溶栓患者，根据患者90 d mRS评分分为预后良好组（0～2分）和预后不良组（＞2分）。收集患者基线临床资料、溶栓前血清3-NT和SerpinB1水平，采用多因素logistic回归分析不良预后的危险因素。
结果共纳入80例接受静脉溶栓治疗的老年急性缺血性卒中患者，其中预后良好组45例，预后不良组35例。预后不良组SerpinB1水平高于预后良好组[（75.24±8.54）ng/mL vs.（57.32±5.68）ng/mL，P<0.001]；预后不良组3-NT水平高于预后良好组[（75.67±11.22）ng/mL vs.（61.68±11.54）ng/mL，P<0.001]。ROC分析显示，当3-NT截断值为70.23 ng/mL时，评估老年急性缺血性卒中患者静脉溶栓预后不良的敏感度为72.54%，特异度为73.28%；SerpinB1截断值为68.17 ng/mL时，评估老年急性缺血性卒中患者静脉溶栓不良预后的敏感度为66.55%，特异度为78.64%。多因素回归分析显示，高NIHSS评分（OR=6.404，95%CI 3.993～10.271，P<0.001）、SerpinB1高水平（OR=26.154，95%CI 11.460～59.690，P<0.001）、3-NT高水平（OR=12.769，95%CI 4.635～35.174，P<0.001）是老年急性缺血性卒中患者静脉溶栓预后不良的危险因素。
结论基线血清3-NT、SerpinB1水平在老年急性缺血性卒中患者静脉溶栓的预后评估中具有一定价值。

关键词: 3-硝基酪氨酸; 丝氨酸蛋白酶抑制剂B1; 急性缺血性卒中; 预后

WANG Le, SHI Qiang, DONG Zhiyan. Value of Serum 3-Nitrotyrosine, Serpin Protease Inhibitors B1 Levels in Predicting Prognosis of Elderly Patients with Acute Ischemic Stroke after Intravenous Thrombolysis [J]. Chinese Journal of Stroke, 2023, 18(12): 1413-1417.

王乐, 师强, 董治燕. 血清3-硝基酪氨酸、丝氨酸蛋白酶抑制剂B1水平对老年急性缺血性卒中患者静脉溶栓预后的预测价值[J]. 中国卒中杂志, 2023, 18(12): 1413-1417.

References

[1] DUPLOMB L，RIVIÈRE J，JEGO G，et al. Serpin B1 defect and increased apoptosis of neutrophils in Cohen syndrome neutropenia[J]. J Mol Med（Berl），2019，97（5）：633-645.
[2] LERMAN I，MA X，SEGER C，et al. Epigenetic suppression of serpinB1 promotes inflammation-mediated prostate cancer progression[J]. Molecular cancer research：MCR，2019，17（4）：845-859.
[3] 刘竞争，黄泽玉，马瑞敏，等. 同型半胱氨酸、血胱抑素C和三酰甘油/高密度脂蛋白胆固醇比值联合检测对出血性脑卒中的诊断价值分析[J]. 标记免疫分析与临床，2022，29（5）：776-779.
LIU J Z，HUANG Z Y，MA R M，et al. A study on the expression and diagnosis of Hcy，Cys-C and TG/HDL-C indicators in hemorrhagic stroke[J]. Labeled Immunoassays & Clin Med，2022，29（5）：776-779.
[4] 邓一鸣，张净瑜，高峰，等. 高龄老年急性缺血性脑卒中患者桥接治疗与直接介入治疗的对比分析[J]. 中华老年医学杂志，2020，39（10）：1137-1141.
DENG Y M，ZHANG J Y，GAO F，et al. A comparative
analysis of bridging therapy versus direct endovascular treatment in acute ischemic stroke patients aged 80 years and over[J]. Chin J Geriatr，2020，39（10）：1137-1141.
[5] CHOI Y J，KIM S，CHOI Y，et al. SerpinB1-mediated checkpoint of inflammatory caspase activation[J]. Nat Immunol，2019，20（3）：276-287.
[6] DAKHEL A，ENGSTRÖM G，MELANDER O，et al. Vasoactive biomarkers associated with long-term incidence of symptomatic peripheral arterial disease and mortality[J]. Angiology，2021，72（6）：550-555.
[7] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志，2018，51（9）：666-682.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Chin J Neurol，2018，51（9）：666-682.
[8] 蒋烽烽，鲍翔，刘晓波，等. 丁苯肽联合瑞舒伐他汀对急性缺血性脑卒中患者神经功能的影响[J]. 重庆医学，2020，49（10）：1580-1584.
JIANG F F，BAO X，LIU X B，et al. Effect of Butylphthalide combined with Rosuvastatin on neurologic function in patients with acute ischemic stroke[J]. Chongqing Yixue，2020，49（10）：1580-1584.
[9] 黄名新，邓晓清. 高血压合并急性缺血性脑卒中患者血清Gal-3水平与预后的关系[J]. 标记免疫分析与临床，2021，28（2）：309-312，317.
HUANG M X，DENG X Q. The relationship between the level of serum Gal-3 and the prognosis of patients with hypertension and acute ischemic stroke[J]. Labeled Immunoassays & Clin Med，2021，28（2）：309-312，317.
[10] 朱一珂，杨君素，钱芳，等. 急性缺血性脑卒中患者血运重建前后NLR值与预后相关性分析[J]. 昆明医科大学学报，2022，43（8）：100-105.
ZHU Y K，YANG J S，QIAN F，et al. Correlation between NLR value and prognosis in patients with acute ischemic stroke before and after revascularization[J]. Journal of Kunming Medical University，2022，43（8）：100-105.
[11] 苗志娟，王修哲. 免疫炎症在缺血性脑卒中的研究进展[J]. 中风与神经疾病杂志，2020，37（1）：87-89.
MIAO Z J，WANG X Z. Research progress of immunoinflammation in ischemic stroke[J]. Journal of Apoplexy and Nervous Diseases，2020，37（1）：87-89.
[12] 朱海锋，成兴波. 2型糖尿病合并颈动脉粥样硬化患者血清丝氨酸蛋白酶抑制剂B1水平变化的研究[J]. 中国糖尿病杂志，2020，28（4）：256-259.
ZHU H F，CHENG X B. Changes of serum level of serine protease inhibitor B1 in patients with type 2 diabetes mellitus complicated with carotid atherosclerosis[J]. Chinese Journal of Diabetes，2020，28（4）：256-259.
[13] HELL L，LURGER K，MAURACHER L M，et al. Altered platelet proteome in lupus anticoagulant（LA）-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis[J]. Exp Mol Med，2020，52（1）：66-78.
[14] 陈双双，武靖，王愉靖，等. 丝氨酸蛋白酶抑制剂通过细胞内吞作用参与调控细胞信号通路的机制的研究现状[J]. 中国临床药理学杂志，2021，37（22）：3189-3192，3203.
CHEN S S，WU J，WANG Y J，et al. Current situation of the mechanism of the Serine protease inhibitor E2 involved in regulating cell signaling pathways through endocytosis[J]. Chin J Clin Pharmacol，2021，37（22）：3189-3192，3203.
[15] 周虹，崔琦，张帅，等. 血清3-NT水平与初诊2型糖尿病患者颈动脉粥样硬化的关系[J]. 山东医药，2020，60（34）：75-78.
ZHOU H，CUI Q，ZHANG S，et al. Relationship between serum 3-NT levels and carotid atherosclerosis in newly diagnosed type 2 diabetes mellitus[J]. Shandong Medical Journal，2020，60（34）：75-78.
[16] GUPTA M，PALIWAL V K，BABU G N. Serum fractalkine and 3-nitrotyrosine levels correlate with disease severity in Parkinson's disease：a pilot study[J]. Metab Brain Dis，2022，37（1）：209-217.